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Endothelin-1 (ET-1) is a potent vasoconstrictor peptide
originally isolated and purified from the conditioned
medium of cultured porcine aortic endothelial cells [1].
It has been shown to process a wide spectrum of bio-
logical activity in the kidneys [2]. ET-1 may play dif-
ferent roles in the diabetic kidney because the diabetic
glomeruli exhibit a poor contractile response to vaso-
active agents and diabetic kidneys do not contract,
even during end-stage renal failure. The synthesis of
ET-1 can be induced by various stimuli, including
shear stress, hypoxia, cytokines, thrombin, angiotensin
II and transforming growth factor-α [3]. All these stim-
uli can be found in renal glomeruli, the functional
unit of the kidneys, and especially in the glomerular
mesangial cells.
ET-1 induces the proliferation of mesangial cells
and the production of extracellular matrix [4]. Cellular
proliferation and increased extracellular matrix are
major factors involved in glomerulosclerosis, playing
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Endothelin-1 (ET-1) plays an important role in the pathogenic mechanism of diabetic nephropathy.
However, the regulatory effects of ET-1 on superoxide and prostaglandin E2 (PGE2) in diabetic
glomeruli are unclear. The aim of this study was to determine whether ET-1 exerts a differential
effect on the production of superoxide and PGE2 in diabetic glomeruli. The regulatory effects of
indomethacin, insulin, dexamethasone, and heparin were also investigated. Freshly isolated
glomeruli were obtained from normal and streptozotocin-induced diabetic rats for 1 week (DM1W),
1 month (DM1M), and 3 months (DM3M), respectively. Our results showed that the basal super-
oxide production of isolated glomeruli was significantly higher in DM1M and DM3M than in the
normal rats (p < 0.01). ET-1 stimulated superoxide production in normal, DM1W and DM1M
glomeruli (p < 0.01) but not in DM3M rats. The basal production of PGE2 in isolated glomeruli did
not differ between diabetic and normal rats. ET-1 also stimulated PGE2 production in diabetic rats
(p<0.05). Pretreatment with indomethacin further enhanced ET-1-stimulated superoxide production
in all groups of diabetic rats (p < 0.05), while the ET-1-stimulated PGE2 production was attenuated
by indomethacin. Insulin, dexamethasone and heparin had no additional effects on ET-1-mediated
superoxide and PGE2 production. In conclusion, basal glomerular production of superoxide but not
PGE2 was increased in the diabetic glomeruli. ET-1 further stimulated production of both super-
oxide and PGE2. Indomethacin could enhance ET-1-stimulated superoxide production while
attenuating PGE2 production.
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important roles in the progression of renal diseases
including diabetes [5]. We have recently demonstrated
both the production of ET-1 and the expression of ET-
1 mRNA is increased in the glomeruli of diabetic rats.
Glomerular production of ET-1 can be enhanced by
superoxide, one of the major reactive oxygen species
(ROS). However, the effects of ET-1 on the production
of superoxide and prostaglandin E2 (PGE2) in the
whole glomerulus, the functional unit and the major
target of diabetic insult, is unclear. This issue becomes
important because ET-1 has been identified as an au-
tocrine cytokine [6]. Therefore, the aim of this study
was to determine whether ET-1 exerts a differential
effect on the production of superoxide and PGE2 in
the diabetic glomeruli. Both are thought to play an
important role in the underlying pathophysiology of
diabetic nephropathy. We also investigated the regula-
tory effects of indomethacin, insulin, dexamethasone,
and heparin on ET-1-mediated production of superox-
ide and PGE2. All these agents have been described
to exert different biological and pharmacological ef-
fects in patients with glomerular disorders. Among
them, indomethacin, a non-steroid anti-inflammatory
drug, is a prostaglandin inhibitor and also the cause
of renal disorders. Insulin, the drug used for treating
diabetes, is known to have anti-oxidative effects [7].
Dexamethasone, a corticosteroid, is the major immu-
nosuppressant for treating immunological renal dis-
orders. Heparin has been reported to regulate ET-1
and superoxide [7].
MATERIALS AND METHODS
Male Wistar rats with a body weight between 200–
250 g were used. Rats were injected with 55 mg/kg 
of streptozotocin (Sigma Chemical Co., St Louis, 
MO, USA) intraperitoneally and used in experiments
after confirming the diagnosis of diabetes mellitus.
Rats were classified into three groups, each contain-
ing 10 rats. The different groups represented different
periods of diabetes. Group I was sacrificed at 1 week
after induction of diabetes (DM1W), Group II was
sacrificed at 1 month (DM1M) and Group III at 3
months (DM3M). All three groups had the same
number of rats sacrificed at the same time to serve 
as normal controls. Group II and III were adminis-
tered insulin (heat-treated bovine ultralente insulin;
Novo-Nordisk, Copenhagen, Denmark) every day to
maintain a poorly controlled diabetic state. Plasma
glucose levels were regularly checked and main-
tained above 450 mg/dL. All rats were allowed food
and water ad libitum. The animal experiment was
approved by the animal committee of Kaohsiung
Medical University.
Experimental protocol
Freshly isolated diabetic or normal rat glomeruli
were stimulated with ET-1 at a concentration of 50 nM.
The concentration was chosen after a dose-response
study. The production of superoxide and PGE2 were
measured at basal levels and after ET-1 stimulation
for 30 minutes. The production of diabetic and normal
glomeruli was conducted with or without indometh-
acin (1.0 μM), insulin (0.3 mU/mL), dexamethasone
(0.1 μM), or heparin (100 μg/mL), and these were pre-
incubated at 37°C for 2 hours before stimulation with
ET-1. To test the effect of insulin, the diabetic or normal
glomeruli were initially incubated with insulin at 4°C
for 90 minutes, and then incubated for 30 minutes at
37°C. It should be emphasized that an initial expo-
sure of diabetic glomeruli to insulin at low tempera-
ture was required for expression of its effects [8]. All
chemicals were purchased from the Sigma (St Louis,
USA) unless otherwise specified.
Preparation of glomeruli
Diabetic and normal rats were anesthetized with pen-
tobarbital and then perfused by aorta puncture with
30 mL Hank’s solution and 10 mL RPMI 1640 medium
[9]. After this, bilateral nephrectomy was performed,
the renal capsule removed, and the renal cortex dis-
sected and removed from the perfused kidneys. The
glomeruli were obtained by pressing minced renal
cortexes through sieves of graded sizes. Using this
method, we could obtain glomeruli at 95% purity.
The viability of the isolated glomeruli was regularly
checked with a lactic dehydrogenase assay. All glomer-
uli were shown to be viable at the end of each experi-
ment. The collected glomeruli were then incubated
on 24-well tissue culture plates at 1 × 104 glomeruli/
mL in RPMI 1640 medium supplemented with 20%
fetal calf serum and antibiotics. All glomeruli were
used immediately after isolation and all experiments
were finished within 6 hours. By the end of each exper-
iment, glomeruli were homogenized and the protein
content was measured using the Bradford assay (Bio-
Rad, Hercules, CA, USA).
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Measurement of superoxide
Superoxide anion production by glomeruli was
determined by measuring the superoxide dismutase-
inhibiting reduction of cytochrome C by a spectropho-
tometer [7]. Briefly, the glomeruli (containing 1 × 104
glomeruli/mL) in phosphate buffered saline contain-
ing Ca2+ (1 mM) and cytochrome C (80 μM) with or
without superoxide dismutase (500 μg/mL) were pre-
incubated for 10 minutes in a 37°C water bath. The
glomeruli were then stimulated with ET-1 at 37°C for
6 hours in a vibrating water bath and the reaction ter-
minated by placing on ice. The absorbance of the su-
pernatant was then measured at 550 nm.
Measurement of PGE2
PGE2 was extracted from the supernatant and mea-
sured using a radioimmunoassay kit (Amersham,
Arlington. Heights, IL, USA). The samples were puri-
fied after adding ethanol and glacial acetic acid and
centrifuged. The supernatant was applied to a C18
Sep-Pak cartridge. After being washed with water and
hexane, the samples were eluted with ethyl acetate
and dried with nitrogen. The extracted samples were
reconstituted with methyl oxidation reagents and
analyzed by radioimmunoassay.
Statistical analysis
All results are expressed as mean±standard error mean.
Unpaired t tests were used to compare differences.
RESULTS
Superoxide production
The basal production of superoxide in isolated nor-
mal glomeruli was 0.84 ± 0.11 nmol/mg glomerular
protein/30 min, which was significantly lower than
that in DM1M and DM3M rats (p < 0.01 for both
groups, Figure 1). The superoxide production was
also significantly higher in the glomeruli isolated
from DM3M rats than that isolated from DM1W rats
(p<0.01). ET-1 enhanced superoxide production in nor-
mal, DM1W, and DM1M groups (all p < 0.01), but not
in the DM3M group. Pretreating the glomeruli with
indomethacin enhanced superoxide production in all
diabetic groups (all p < 0.05) but not in the normal
controls, while insulin, dexamethasone and heparin
did not have an effect in any of the groups (Table 1).
PGE2 production
Basal production of PGE2 in isolated normal glo-
meruli was 1.28 ± 0.22 ng/mg glomerular protein/30
min, which did not significantly differ from any of the
diabetic groups (Figure 2), also the glomerular PGE2
Table 1. Superoxide production in freshly isolated glomeruli after stimulating with endothelin-1 for 30 minutes with
or without indomethacin, insulin, dexamethasone and heparin in normal and streptozotocin-induced diabetic rats*
Superoxide (nmol/mg glomerular protien/30 min)
Treatment
Normal DM1W DM1M DM3M
ET-1 only 5.12 ± 0.87 3.97 ± 0.28 3.16 ± 0.21 3.08 ± 0.20
ET-1 + indomethacin 4.99 ± 0.21 4.96 ± 0.32† 3.87 ± 0.20† 3.82 ± 0.19†
ET-1 + insulin 5.01 ± 0.38 4.09 ± 0.29 3.22 ± 0.30 3.12 ± 0.19
ET-1 + dexamethasone 5.33 ± 0.39 3.88 ± 0.21 3.09 ± 0.27 3.28 ± 0.18
ET-1 + heparin 5.20 ± 0.47 3.69 ± 0.37 3.19 ± 0.27 3.01 ± 0.21
*Data presented as mean ± standard error mean of triplicate samples from six independent experiments; †p < 0.05 compared with ET-1
group. ET-1 = endothelin-1; DM1W = diabetic rats for 1 week; DM1M = diabetic rats for 1 month; DM3M = diabetic rats for 3 months.
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Figure 1. Superoxide production of freshly isolated rat glomeruli
stimulated with or without endothelin-1 treatment (50 nM) for
30 minutes in normal and streptozotocin-induced diabetic rats.
Data are mean ± standard error mean of triplicate samples from
six independent experiments. *p < 0.01 for comparison between
rats with and without ET-1 at the same time point; †p < 0.01 for
comparison of rats without ET-1 to normal; ‡p<0.01 for comparison
of rats without ET-1 to DM1W. ET-1 = Endothelin-1; DM1W =
diabetic rats for 1 week; DM1M = diabetic rats for 1 month;
DM3M = diabetic rats for 3 months.
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production did not significantly differ between any
of the diabetic groups. ET-1 enhanced PGE2 produc-
tion in all the diabetic groups (all p < 0.05) but not in
the normal controls. Pretreating the glomeruli with
indomethacin attenuated ET-1-enhanced PGE2 pro-
duction in normal and all diabetic groups (p < 0.05 for
normal control and DM1W, p < 0.005 for DM1M and
DM3M), while insulin, dexamethasone and heparin
did not exert any effect in those groups (Table 2).
DISCUSSION
In this study, we demonstrated that basal production
of superoxide but not PGE2 was increased in freshly
isolated diabetic glomeruli. ET-1 further enhanced
production of both superoxide and PGE2 in diabetic
glomeruli. The kidney is an important organ for the
synthesis of ET-1. We previously demonstrated basal
ET-1 production of diabetic glomeruli increased with
the progression of diabetes [10], and insulin added 
in vitro partially attenuated ET-1 production by diabetic
glomeruli. The major cause of increased basal ET-1
production by diabetic glomeruli may be hypergly-
cemia, as we found that high glucose concentration
in vitro enhanced ET-1 production in normal glomeruli
[10]. There have been several studies demonstrating
that ET-1 receptors are widespread in the kidneys
[11,12]. Overexpression of endothelin receptors can be
found in the renal cortex of diabetic rats [12], and endo-
thelin receptor antagonists can prevent the progres-
sion of diabetic nephropathy [13,14]. Therefore, the
effects of ET-1 on isolated glomeruli can be expected.
Freshly isolated glomeruli are the best materials
for studying living tissues, since nearly all the glomer-
uli have been shown to be viable by the end of the
study. Basal production of cytokines or hormones
under this condition mimics the in vivo status, and
reflects the results of various interactions common in
the glomerulus. We have demonstrated that basal
production of superoxide is increased in isolated dia-
betic glomeruli compared with normal controls, and
production increased further with the progression of
diabetes. Superoxide is the major ROS which has been
implicated in the pathogenesis of diabetic nephropa-
thy [10]. Glomeruli have been shown to generate
ROS [15], and there is considerable evidence suggest-
ing generation of ROS increases in diabetes [16,17]
and in acute hyperglycemia [18]. During diabetes,
persistent hyperglycemia causes increased produc-
tion of ROS through autoxidation of glucose and by
non-enzymatic protein glycation, which may not only
disrupt cellular functions [17] but also inactivate the
endogenous ROS scavengers including superoxide
dismutase and catalase [19], causing an endogenous
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Figure 2. Prostaglandin E2 production in freshly isolated rat
glomeruli treated with or without endothelin-1 treatment (50 nM)
for 30 minutes in normal and streptozotocin-induced diabetic rats.
Data presented as mean± standard error mean of triplicate samples
from six independent experiments. *p < 0.05 for comparison be-
tween rats with and without ET-1 treatment at the same time point.
Table 2. Prostaglandin E2 production in freshly isolated glomeruli after stimulating with endothelin-1 with or without
indomethacin, insulin, dexamethasone and heparin in normal and streptozotocin-induced diabetic rats normal and
diabetic glomeruli*
Prostaglandin E2 (ng/mg glomerular protein/30 min)
Treatment
Normal DM1W DM1M DM3M
ET-1 only 1.48 ± 0.37 2.58 ± 0.47 3.12 ± 0.56 3.34 ± 0.64
ET-1 + indomethacin 0.32 ± 0.19† 0.86 ± 0.47† 0.69 ± 0.30‡ 1.04 ± 0.28‡
ET-1 + insulin 1.26 ± 0.52 2.62 ± 0.98 3.42 ± 1.08 3.15 ± 0.88
ET-1 + dexamethasone 1.82 ± 0.69 2.23 ± 0.84 2.89 ± 1.19 2.66 ± 0.64
ET-1 + heparin 1.32 ± 0.86 2.78 ± 0.69 2.97 ± 0.76 2.87 ± 0.54
*Data presented as mean ± standard error mean of triplicate samples from six independent experiments; †p < 0.05 compared to ET-1
group; ‡p < 0.005 compared to ET-1 group. ET-1 = endothelin-1; DM1W = diabetic rats for 1 week; DM1M = diabetic rats for 1 month;
DM3M = diabetic rats for 3 months.
oxidant/antioxidant imbalance. Superoxide is one of
the major ROS that may be stimulated by high glucose.
The mechanisms by which hyperglycemia enhances
superoxide production may be through activating the
protein kinase C (PKC) system. The PKC of glomeruli
from streptozotocin-induced diabetic rats have been
reported to be activated within 1 week after induc-
tion of diabetes [20]. The exposure of normal isolated
glomeruli to a high ambient concentration of glucose
also activates PKC [20], and PKC has been shown to
mediate the generation and release of superoxide [21].
We have also demonstrated that ET-1 enhanced
glomerular production of superoxide in normal,
DM1W, and DM1M rats, respectively. However, the
ET-1-enhanced superoxide production decreased
progressively with the duration of diabetes, and it was
not significantly different after ET-1 stimulation in the
DM3M group. The results indicate that longer duration
of diabetes is associated with a refractory response to
ET-1 upon ROS generation.
We also found that basal PGE2 production was not
increased in diabetic glomeruli, while it was increased
significantly after ET-1 stimulation. Basal production of
PGE2 by isolated diabetic glomeruli has been reported
to be either higher [22,23] or unchanged [24] compared
with normal glomeruli. However, their response to
ET-1 has not been reported. ET-1 stimulates vascular
smooth muscles and mesangial cells to release PGE2,
which can attenuate the vasoconstrictor and mito-
genic effects of this peptide. In glomerular mesangial
cells, PGE2 may be an important negative feedback
modulator of ET-1-stimulated cellular contraction. ET-1
markedly increased PGE2 release by rat mesangial
cells for at least 6 hours [25]. Inhibition of prosta-
glandin synthesis with non-steroid anti-inflammatory
drugs enhances the constrictor actions of Angiotensin II
and ET-1 on the vasculature of the kidney and on the
glomerulus. The enhanced production of prostaglan-
dins, in response to constrictor peptides, is both short-
term and long-term. Therefore, ET-1 stimulation over
the short-term and the long-term activates a modula-
tory feedback pathway that depends on upregulation
of arachidonic acid release through phospholipase
A2 and enhanced synthesis of prostaglandin [26].
These abnormalities in prostaglandin biosynthesis by
diabetic glomeruli may contribute to the altered glo-
merular hemodynamics in this pathophysiologic set-
ting. Another study showed that ET-1 evokes PGE2
production in mesangial cells through activating
phospholipase A2 [27]. Increased PGE2 production
has been reported in diabetic placenta compared with
controls, but these levels are not modulated by ET-1
[28]. ET-1 concentrations were found to be increased
in embryos from streptozotocin diabetic rats compared
with controls. However, addition of ET-1 or bosentan
(an endothelin A and endothelin B receptor antago-
nist) did not alter PGE2 generation in embryos from
either the control or streptozotocin diabetic rats [29].
ET-1 is an autocrine peptide and therefore the
effects of ET-1 on diabetic glomeruli in vivo are un-
avoidable. Since many drugs have been proposed to be
effective in treating glomerular disorders, we have ob-
served the protective effects of four of them on isolated
glomeruli. We found indomethacin further enhanced
ET-1-enhanced superoxide production. Superoxide not
only induces lipid peroxidation but also enhances the
formation of oxidized-low density lipoproteins with the
consequence of further glomerular injury. Therefore,
indomethacin may further worsen renal function in dia-
betic nephropathy. Insulin, dexamethasone and heparin
did not have any additional effects on ET-1-mediated
superoxide production. In contrast, indomethacin sup-
pressed ET-1-enhanced PGE2 production of normal and
diabetic glomeruli, further emphasizing its deleteri-
ous effects on diabetic kidneys. Although dexametha-
sone has been reported to decrease ET-1-stimulated
PGE2 release in glomerular mesangial cells [25], we
did not find similar effects on the isolated glomeruli.
Therefore, the results of studies on glomerular cells may
not be directly applied to functional glomeruli.
In conclusion, our results suggest the basal produc-
tion of superoxide was enhanced, while that of PGE2
was unchanged in freshly isolated diabetic glomeruli,
and ET-1 further enhanced the production of both
superoxide and PGE2. Indomethacin enhanced ET-1-
mediated superoxide production while attenuating
PGE2 production, and can apparently worsen diabetic
nephropathy. There are no additional effects of insu-
lin, dexamethasone and heparin on ET-1 mediated
production of superoxide and PGE2.
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內皮素 -1 誘發游離糖尿病腎絲球之
過氧化物侑前列腺素 E2 製造增加
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內皮素 -1（以下簡稱 ET-1）作用於糖尿病腎臟，也許有其重要的角色。因為糖尿病
腎絲球收縮反應較差，而且就算已經末期腎病，糖尿病腎臟也很少萎縮，本研究之目
的即是探討 ET-1是否直接對糖尿病腎絲球作用。本實驗將糖尿病大鼠的腎絲球，自
以 Streptozotocin 誘發糖尿病後 1 週（以下簡稱 DM1W），1 個月（以下簡稱 
DM1M），及 3 個月（以下簡稱 DM3M）時取出，研究觀察 ET-1 對腎絲球產生過
氧化物及前列腺素 E2 （以下簡稱 PGE2）的影響。結果發現，大鼠游離腎絲球之過氧
化物的基礎產量，在 DM1M，DM3M 比正常對照組高 (p < 0.01) ，加入 ET-1 會增
強正常、DM1W及 DM1M 大鼠腎絲球的過氧化物產量（p < 0.01），但 DM3M無
此現象。大鼠腎絲球 PGE2的基礎產量，在糖尿病組和正常對照組並無差別，ET-1 
則會增強各組糖尿病大鼠的腎絲球 PGE2 產量（all p < 0.05）。以 Indomethacin 
前處理，會增強 ET-1 刺激糖尿病組產生過氧化物的作用，但會減弱 ET-1 增強 PGE2 
產生的作用。另外 Insulin，Dexamethasone，及 Heparin 之前處理則無影響。本
研究結論，糖尿病大鼠腎絲球的基礎過氧化物的產量較高，ET-1 刺激會更增強其過
氧化物及 PGE2 的產生；加入 Indomethacin 則會增強 ET-1 所造成的過氧化物產量
增加，但會減弱 PGE2 的產生。
關鍵詞：糖尿病大鼠，內皮素 -1，游離腎絲球，前列腺素 E2，過氧化物
（高雄醫誌 2010;26:350–6）
